ELYM ELIEM THERAPEUTICS INC

Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference

Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference

WELLESLEY, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced that members of its executive team will participate at the 24th Annual Needham Healthcare Conference being held virtually April 7-10, 2025.

24th Annual Needham Virtual Healthcare Conference

Format: Presentation and one-on-one investor meetings

Date: April 10, 2025

Time: 8:45 a.m. ET

Webcast: 

About Climb Bio, Inc.

Climb Bio, Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s pipeline includes, budoprutug, an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases, and CLYM116, an anti-APRIL monoclonal antibody currently in IND-enabling studies for IgA nephropathy. For more information, please visit . 

Investors

Chris Brinzey

ICR Healthcare



339-970-2843

Media

Jon Yu

ICR Healthcare



475-395-5375



EN
27/03/2025

Underlying

ELYMELIEM THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ELIEM THERAPEUTICS INC

 PRESS RELEASE
Free
ELYM ELIEM THERAPEUT...

Climb Bio Reports First Quarter 2025 Financial Results and Provides Bu...

Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates Clinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), Immune Thrombocytopenia (ITP), and Systemic Lupus Erythematosus (SLE) on Track to Initiate in 2025 CLYM116 Progressing Towards Anticipated IND or CTA Submission in Second Half 2025 Appointed Kim Cobleigh Drapkin, CPA, and Bo Cumbo as Independent Directors and Perrin Wilson, Ph.D., as Chief Business Officer Strong Financial Position, with Cash Runway Expected Through 2027 WELLESLEY HILLS, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Cli...

May 14, 2025 1 EN
 PRESS RELEASE
Free
ELYM ELIEM THERAPEUT...

Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors Appointments Include Industry Veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo as Independent Directors WELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors. Ms. Drapkin will assume the role of Audit Committee Chair, and Mr. Cumbo will assume the role of Compensation Committee Chair. “We are delighted to welcome Kim and Bo to our Board of Directors at Climb B...

April 1, 2025 1 EN
 PRESS RELEASE
Free
ELYM ELIEM THERAPEUT...

Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Con...

Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference WELLESLEY, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced that members of its executive team will participate at the 24th Annual Needham Healthcare Conference being held virtually April 7-10, 2025. 24th Annual Needham Virtual Healthcare Conference Format: Presentation and one-on-one investor meetingsDate: April 10, 2025Time: 8:45 a.m. ETWebcast:  About Climb Bio, Inc. Climb Bio, Inc. is a clinical-stage biotechnology company developing therapeutics for patients with im...

March 27, 2025 1 EN
 PRESS RELEASE
Free
ELYM ELIEM THERAPEUT...

Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results a...

Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates Received Clearance from the U.S. Food and Drug Administration (FDA) for Clinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), Immune Thrombocytopenia (ITP), and Systemic Lupus Erythematosus (SLE) Completed Studies to Support Process Optimization through Cell Line Switch for Budoprutug and Filed Additional Patent Applications to Further Strengthen Intellectual Property Position Expanded Pipeline to Include CLYM116, an Anti-APRIL (A PRoliferation-Inducing Ligand) Monoc...

March 25, 2025 1 EN
 PRESS RELEASE
Free
ELYM ELIEM THERAPEUT...

Climb Bio to Present at Upcoming Investor Conferences

Climb Bio to Present at Upcoming Investor Conferences WELLESLEY, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced that members of its executive team will participate in the upcoming investor conferences detailed below. TD Cowen 45th Annual Health Care Conference Format: Formal presentation and one-on-one investor meetingsDate: March 4, 2025Time: 9:50 a.m. ETWebcast:  Leerink’s Global Healthcare Conference 2025Format: Fireside chat and one-on-one investor meetings Date: March 10, 2025Time: 10:00 a.m. ETWebcast: About Climb Bio, Inc. Climb Bio, Inc...

February 25, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch